Alembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts more than Nifty Microcap 250 and 2.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals reported Q2 FY26 consolidated revenue from operations of Rs. 1,910 crore, up about 16% YoY from Rs. 1,648 crore in Q2 FY25. Consolidated profit before tax stood at Rs. 224 crore versus Rs. 190 crore a year ago, with no exceptional item in the current quarter (prior year had Rs. 12.87 crore exceptional income from a Sikkim flood insurance claim). For H1 FY26, consolidated revenue was Rs. 3,621 crore versus Rs. 3,210 crore, and consolidated PBT was Rs. 414 crore. Standalone Q2 revenue grew to Rs. 1,796 crore from Rs. 1,580 crore. The board also noted that the US subsidiary completed the acquisition of UK-based Utility Therapeutics on July 2, 2025, recognizing an intangible asset of Rs. 222 crore (USD 25 million). The statutory auditor's review report is unqualified.
Modest top-line growth and steady profitability, with a meaningful overseas acquisition adding an intangible asset of Rs. 222 crore to the balance sheet. The change of statutory auditor to KKC & Associates LLP (replacing K C Mehta & Co LLP) is a governance point investors should note, though the review conclusion remains unqualified.